Raised £1.2m in October 2015 from a syndicate of UK business Angels to continue our work at developing High Content based personalized chemotherapy.

Moved to our new premises at City Labs 1.0 located in the heart of the Manchester Royal Infirmary, the most prominent hospital in Greater Manchester. Please see below for our new address details

Changing our name from Imagen Biotech to Imagen Therapeutics

Appointed Professor Justin Stebbing (Harley Street & Imperial College, London) as our honorary chief medical advisor.

Completed a 60 patient study in ovarian cancer and initial clinical match up data on the first 28 samples demonstrated an assay accuracy rate of 96%.

Part of the MasterPlans consortium to examine the personalization of LUPUS treatments.

Part of a consortium on a EU Framework 7 award: Rheumatoid arthritis and periodontal inflammatory disease.

Imagen Therapeutics

Suit 4D Citylabs
Nelson Street
Manchester M13 9NQ

<div class="TextBody"> <h3>Cancer is not a single disease. In fact, every cancer is its own unique creation being derived from the unique genetics of the individual combined with the particular mutations that are driving the malignancy. Yet, in most cases, the model for cancer treatment involves using a very limited set of chemotherapies that have been tested for a cancer that is derived from a particular tissue without consideration for the molecular biology that is actually causing the unregulated cell division which is the basis of all cancers.</h3> <h4>Imagen Biotech wants to change this.</h4> <p>Our sole aim is to help get the right chemotherapy to the right patient as fast as possible. We do this by measuring the effectiveness of a wide range of available chemotherapy drugs to kill a cancer sample that has been derived directly from the patient using a very modern technology known as High Content Analysis.</p> <h4>So how many chemotherapies are now out there?</h4> <p>The short answer is lots. We routinely test 56 different therapies although even this is not an exhaustive list of the number of therapies on the market.</p> <h4>How many chemotherapies are used in the treatment of a particular cancer?</h4> <p>Very few!. If you are suffering from glioblastoma then your standard treatment option is radiotherapy and temozolomide. Even difficult to treat cancers which have been extensively researched still have surprisingly few treatment options. For example, ovarian cancer is mostly treated with either cisplatin, carboplatin, doxirubicin or some other standard chemotherapy combination.</p> <p><b>Imagen Biotech</b> is developing a test which aims to find the best chemotherapy for the patient out of all the available options on the market. Ultimately, we want to do this independent of whether the therapy we suggest is licensed for that particular patient's cancer. This strategy will allow patients, who are highly responsive to modern chemotherapies, to be effectively matched to these therapies hence improving their overall prognosis and quality of life.</p> <hr/> </div>